Search results for "Propanol"

showing 7 items of 217 documents

New strategies for medical management of overactive bladder in children.

2011

Purpose of review The medical treatment of children with non-neurogenic overactive bladder syndrome (OAB) is still limited to a small number of drugs approved for use in childhood according to the national regulations of each country. Recent findings Over the last few years, there were several studies on the use of antimuscarinics other than oxybutynin in children, as well as some on the use of extended release oxybutynin and tolterodine and transdermal oxybutynin. It was shown that the combination of two different anticholinergics might be a well tolerated and successful option in children with OAB refractory to monotherapy, as well as administration of a receptor-selective antimuscarinic …

medicine.medical_specialtyQuinuclidinesBotulinum ToxinsCombination therapyTolterodine TartrateNortropanesUrologyPhenylpropanolamineUrologyUrinationMuscarinic AntagonistsBenzilatesCresolsTetrahydroisoquinolinesmedicineHumansBenzhydryl CompoundsOxybutyninIntensive care medicineChildSolifenacinbusiness.industryUrinary Bladder OveractiveStandard treatmentSolifenacin Succinatemedicine.diseaseBotulinum toxinReceptors MuscarinicOveractive bladderMandelic AcidsPropiverineTolterodinebusinessmedicine.drugCurrent opinion in urology
researchProduct

Oral Propranolol for Circumscribed Choroidal Hemangioma

2011

Introduction: Several therapeutic approaches have been developed to treat choroidal hemangioma. However, all these therapies are associated with a potential risk of damaging the overlying retina. Case Report: We report a case of circumscribed choroidal hemangioma (CCH) in a 59-year-old man refractory to laser treatment. Visual acuity was 20/200 and a serous macular detachment was present. The CCH was treated with oral propanolol, whereupon visual acuity improved to 20/20 and the macular detachment resolved without systemic or local adverse effects. Discussion: Propanolol is a β-blocker commonly used in cardiology that may induce endothelium vasoconstriction and inhibit endothelial prolifera…

medicine.medical_specialtyVisual acuityEndotheliumCircumscribed choroidal hemangiomaPropranololβ-Blockerlcsh:OphthalmologyOphthalmologymedicineCircumscribed choroidal hemangiomaAdverse effectRetinaEndothelial proliferationbusiness.industryβ-Blockereye diseasesSurgeryOphthalmologyPublished: February 2011medicine.anatomical_structurelcsh:RE1-994sense organsmedicine.symptombusinessVasoconstrictionmedicine.drugPropanololCase Reports in Ophthalmology
researchProduct

Clinical pharmacokinetics of atenolol — A review

1982

Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. After oral administration atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally biovailable. In plasma only 3% of atenolol are protein-bound. There exists a linear relationship between the atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia. No correlation was found between plasma levels of atenolol and blood pressure lowering activity of the drug. After oral administration elimination half life of atenolol is calcula…

medicine.medical_specialtymedicine.drug_classAdministration OralBiological AvailabilityRenal functionPharmacologyKidneyIntestinal absorptionPropanolaminesPharmacokineticsRenal DialysisOral administrationInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)cardiovascular diseasesBeta blockerPharmacologyChemistryLiver DiseasesKidney metabolismAtenololKineticsEndocrinologyAtenololIntestinal AbsorptionInjections IntravenousKidney DiseasesBiological half-lifecirculatory and respiratory physiologymedicine.drugEuropean Journal of Drug Metabolism and Pharmacokinetics
researchProduct

Zn,Al hydrotalcites calcined at different temperature: Characterisation and photocatalytic activity for the degradation of 2-propanol in gas-solid re…

2009

photocatalysi2-propanolSettore CHIM/07 - Fondamenti Chimici Delle Tecnologiehydrotalcites
researchProduct

Binary Materials TiO2 or ZnO-Activated Carbon Used as Photomediators in the Photocatalytic Degradation of 2-Propanol in Gas-Solid Regime

2010

photocatalysiactive carbon2-propanolTiO2Zn§OSettore CHIM/07 - Fondamenti Chimici Delle Tecnologie
researchProduct

Influence of activated carbon in the TiO2 mediated photo-assisted degradation of 2-propanol in gas-solid regime

2009

photocatalysititanium dioxideActivated carbon2-propanolSettore CHIM/07 - Fondamenti Chimici Delle Tecnologie
researchProduct

CCDC 172703: Experimental Crystal Structure Determination

2002

Related Article: M.Dey, C.P.Rao, P.K.Saarenketo, K.Rissanen|2002|Inorg.Chem.Commun.|5|380|doi:10.1016/S1387-7003(02)00407-0

tetrakis((mu~3~-2-Methyl-2-(salicyclideneamino)propanolato)-copper(ii)) tetrahydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct